Destiny Pharma PLC Exercise of Options (3478V)
06 April 2019 - 3:06AM
UK Regulatory
TIDMDEST
RNS Number : 3478V
Destiny Pharma PLC
05 April 2019
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Exercise of Options
Brighton, United Kingdom - 5 April 2019 - Destiny Pharma (AIM:
DEST), a clinical stage biotechnology company focused on the
development of novel antimicrobial drugs, which address the global
problem of antimicrobial resistance (AMR), today announces that it
has issued 50,000 new ordinary shares of 1 pence each in the
capital of the Company (the "New Ordinary Shares") following an
exercise of share options by a former employee.
Application will be made to the London Stock Exchange for the
New Ordinary Shares to be admitted to trading on AIM, with dealings
expected to commence on 12 April 2019 ("Admission").
Following Admission, the Company will have a total of 43,865,195
Ordinary Shares in issue. Shareholders may use this figure of
43,865,195 Ordinary Shares as the denominator for the calculations
by which they will determine if they are required to notify their
interest in, or a change to their interest in, the share capital of
the Company under the FCA's Disclosure Guidance and Transparency
Rules.
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
pressoffice@destinypharma.com
+44 (0)1273 704 440
FTI Consulting
Simon Conway / Victoria Foster Mitchell
destinypharma@fticonsulting.com
+44 (0) 20 3727 1000
Cantor Fitzgerald Europe (Nominated Adviser and Joint
Broker)
Philip Davies / Will Goode, Corporate Finance
Andrew Keith, Healthcare Equity Sales
+44 (0)20 7894 7000
finnCap Ltd (Joint Broker)
Geoff Nash /Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0)20 7220 0500
About XF-73
XF-73 is a synthetic anti-microbial active against all tested
Staphylococcus aureus strains, including drug resistant strains. By
acting via a cell-surface mechanism it affects the bacterial
membrane permeability and integrity, leading to cell death. XF-73
has already been through five successful Phase I/IIb clinical
trials showing rapid antibacterial action. In standard microbiology
studies XF drugs have demonstrated a unique no/low resistance
profile that means that XF compounds have the potential to deliver
novel drugs that are clearly differentiated from traditional
antibiotics where resistance limits their utility.
XF-73 is being studies for the prevention of post-surgical
staphylococcal infections. In the US, there are approximately 40
million surgeries per annum alone where the patient is at risk of a
post-surgical infection. However, within this large population
there are particular groups who are at an even higher risk of
infection due to the nature of their surgery or the procedures
and/or their specific hospital environment in which they are
treated. These higher risk surgical procedures include
cardiovascular, orthopaedic and other complex surgeries. Destiny
Pharma estimates that this totals approximately 14 million US
surgeries per year, with this figure set to rise within the context
of an ageing population.
About Destiny Pharma
Destiny Pharma is an established, clinical stage, innovative
biotechnology company focused on the development of novel medicines
that represent a new approach to the treatment of infectious
disease. These potential new medicines are being developed to
address the need for new drugs for the prevention and treatment of
life-threatening infections caused by antibiotic-resistant
bacteria, often referred to as "superbugs". Tackling anti-microbial
resistance has become a global imperative recognised by the WHO and
the United Nations, as well as the G7 and the G20 countries. For
further information, please visit https://www.destinypharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOEGMGGDVKDGLZM
(END) Dow Jones Newswires
April 05, 2019 12:06 ET (16:06 GMT)
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From Apr 2024 to May 2024
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From May 2023 to May 2024